Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TGX > SEC Filings for TGX > Form 8-K on 9-May-2013All Recent SEC Filings

Show all filings for THERAGENICS CORP | Request a Trial to NEW EDGAR Online Pro



Results of Operations and Financial Condition, Costs Associated with Exit or Dis

Item 2.02. Results of Operations and Financial Condition.

On May 9, 2013, Theragenics Corporation (the "Company") issued a press release regarding its consolidated financial results for the quarter ended March 31, 2013. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Item 2.05. Costs Associated with Exit or Disposal Activities.

On May 8, 2013 the Company's Board of Directors approved a restructuring plan for the Company's vascular access manufacturing operations that will involve, among other things, closing the Company's vascular access manufacturing facility in Garland, Texas by the end of 2014 (the "Restructuring"). Most of the plant's manufacturing operations will be outsourced to independent suppliers in Latin America, and the more complex manufacturing operations will be moved to the Company's specialty needle plant in North Attleboro, Massachusetts. The Restructuring is scheduled to commence in the second quarter of 2013 and is expected to be completed by the end of 2014. The Company will retain the Galt Medical brand and continue to market and sell the full line of Galt vascular access products.

These actions are designed to reduce manufacturing costs and to allow the Company to remain competitive in a highly competitive marketplace. The Company expects to incur incremental expenses related to the Restructuring totaling approximately $3.7 to $4.1 million through 2014, of which approximately $2.0 to $2.2 million represent severance related costs. The incremental expenses related to the Restructuring, substantially all of which represent cash expenditures, will be recorded and paid over time as the plan is implemented. The Company also expects to make $2.5 to $2.7 million of capital expenditures in cash related to the Restructuring and outsourcing program through 2014.

The estimated incremental expenses related to the Restructuring and capital expenditures noted above are estimates which are subject to change. Actual results may be materially different.

The Company announced these plans in its May 9, 2013 press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Item

99.1 Press release dated May 9, 2013 of Theragenics Corporation

  Add TGX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TGX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.